Leo Pharma expands its arsenal of arguments for Adtralza with new long-term data
While Leo Pharma is in full swing with getting eczema treatment Adtralza onto the market, and is anxiously waiting on US approval, the company has presented new long-term data for the drug, causing excitement.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Leo Pharma has been developing the medicine tralokinumab for so long that it can now present data for the treament stretching over two years. The drug was already approved earlier this year as a treatment for atopic dermatitis in the EU under the name Adtralza.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
